MT Newswires
Ideaya Biosciences Says 1st Patient Enrolled in Phase 1 Clinical Trial of Solid Tumors; Shares Up Pre-Bell
📊
AI Sentiment
Positive
7/10
- Home
- GILD
GILD
Gilead Sciences Inc.
as of 03-09-2026 3:18pm EST
$145.31
+$1.38
+0.96%
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 187.5B | IPO Year: | 2000 |
| Target Price: | $143.50 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 6.78 | EPS Growth: | 1684.21 |
| 52 Week Low/High: | $95.30 - $157.29 | Next Earning Date: | 05-13-2026 |
| Revenue: | $24,689,000,000 | Revenue Growth: | 9.98% |
| Revenue Growth (this year): | 4.68% | Revenue Growth (next year): | 6.10% |
| P/E Ratio: | 21.23 | Index: | |
| Free Cash Flow: | 9.5B | FCF Growth: | -8.24% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Feb 27, 2026
Avg Cost/Share
$144.97
Shares
10,000
Total Value
$1,447,858.62
Owned After
642,308
Dickinson Andrew D
Sell
Chief Financial Officer
GILD Feb 17, 2026
Avg Cost/Share
$154.43
Shares
3,000
Total Value
$463,290.00
Owned After
167,779
SEC Form 4
Mercier Johanna
Sell
Chief Comm & Corp Aff Officer
GILD Feb 17, 2026
Avg Cost/Share
$154.90
Shares
28,000
Total Value
$4,324,227.86
Owned After
129,883
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Feb 5, 2026
Avg Cost/Share
$150.00
Shares
115,640
Total Value
$17,346,000.00
Owned After
642,308
SEC Form 4
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Jan 28, 2026
Avg Cost/Share
$139.89
Shares
10,000
Total Value
$1,398,911.15
Owned After
642,308
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Jan 23, 2026
Avg Cost/Share
$135.00
Shares
115,640
Total Value
$15,611,400.00
Owned After
642,308
SEC Form 4
Bluestone Jeffrey
Sell
Director
GILD Jan 20, 2026
Avg Cost/Share
$123.50
Shares
5,000
Total Value
$617,500.00
Owned After
8,920
SEC Form 4
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Dec 29, 2025
Avg Cost/Share
$124.83
Shares
10,000
Total Value
$1,248,272.00
Owned After
642,308
SEC Form 4
Dickinson Andrew D
Sell
Chief Financial Officer
GILD Dec 15, 2025
Avg Cost/Share
$122.00
Shares
3,000
Total Value
$366,000.00
Owned After
167,779
SEC Form 4
Mercier Johanna
Sell
Chief Commercial Officer
GILD Dec 15, 2025
Avg Cost/Share
$122.00
Shares
3,000
Total Value
$366,000.00
Owned After
129,883
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | GILD | Chairman & CEO | Feb 27, 2026 | Sell | $144.97 | 10,000 | $1,447,858.62 | 642,308 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Feb 17, 2026 | Sell | $154.43 | 3,000 | $463,290.00 | 167,779 | |
| Mercier Johanna | GILD | Chief Comm & Corp Aff Officer | Feb 17, 2026 | Sell | $154.90 | 28,000 | $4,324,227.86 | 129,883 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Feb 5, 2026 | Sell | $150.00 | 115,640 | $17,346,000.00 | 642,308 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Jan 28, 2026 | Sell | $139.89 | 10,000 | $1,398,911.15 | 642,308 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Jan 23, 2026 | Sell | $135.00 | 115,640 | $15,611,400.00 | 642,308 | |
| Bluestone Jeffrey | GILD | Director | Jan 20, 2026 | Sell | $123.50 | 5,000 | $617,500.00 | 8,920 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Dec 29, 2025 | Sell | $124.83 | 10,000 | $1,248,272.00 | 642,308 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Dec 15, 2025 | Sell | $122.00 | 3,000 | $366,000.00 | 167,779 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Dec 15, 2025 | Sell | $122.00 | 3,000 | $366,000.00 | 129,883 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 10, 2026 · 100% conf.
AI Prediction BUY
1D
+5.92%
$156.54
5D
+6.36%
$157.19
20D
+7.71%
$159.20
Price: $147.80 Prob +5D: 100% AUC: 1.000
0000882095-26-000003
gild-202602100000882095false00008820952026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 10, 2026
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware0-1973194-3047598 (State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)
333 Lakeside Drive, Foster City, California (Address of principal executive offices) 94404 (Zip Code) 650-574-3000 (Registrant’s Telephone Number, Including Area Code)
Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 2 - FINANCIAL INFORMATION
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2026, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter and year ended December 31, 2025. A copy of the press release is filed as Exhibit 99.1 to this report.
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 11, 12, 13 and 14 of the press release filed as Exhibit 99.1 to this report.
The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on February 10, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
(Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer
Date: February 10, 2026
Exhibit Index
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on February 10, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0000882095-25-000044
gild-202510300000882095false00008820952025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 30, 2025
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware0-1973194-3047598 (State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)
333 Lakeside Drive, Foster City, California (Address of principal executive offices) 94404 (Zip Code) 650-574-3000 (Registrant’s Telephone Number, Including Area Code)
Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 2 - FINANCIAL INFORMATION
Item 2.02 Results of Operations and Financial Condition.
On October 30, 2025, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended September 30, 2025. A copy of the press release is filed as Exhibit 99.1 to this report.
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 9, 10 and 11 of the press release filed as Exhibit 99.1 to this report.
The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on October 30, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
(Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer
Date: October 30, 2025
Exhibit Index
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on October 30, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000882095-25-000030
gild-202508070000882095false00008820952025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 7, 2025
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware0-1973194-3047598 (State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)
333 Lakeside Drive, Foster City, California (Address of principal executive offices) 94404 (Zip Code) 650-574-3000 (Registrant’s Telephone Number, Including Area Code)
Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 2 - FINANCIAL INFORMATION
Item 2.02 Results of Operations and Financial Condition.
On August 7, 2025, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is filed as Exhibit 99.1 to this report.
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10, 11 and 12 of the press release filed as Exhibit 99.1 to this report.
The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on August 7, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
(Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer
Date: August 7, 2025
Exhibit Index
Exhibit NumberDescription 99.1 Press Release, issued by Gilead Sciences, Inc. on August 7, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Simply Wall St.
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Gilead’s BIC LEN HIV Results Highlight Valuation Gap And Future Potential
📈
AI Sentiment
Highly Positive
8/10
MarketBeat
These 3 Cash Flow Machines Provide Stability in Uncertain Markets
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Gilead Sciences' HIV Drug Eyed for Local Production by South Africa
➖
AI Sentiment
Neutral
5/10
PR Newswire
Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
📈
AI Sentiment
Highly Positive
9/10
Compare GILD vs Leading Stocks
See how GILD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.